INSM Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.…
Industry Peers
BiotechnologyKey Statistics
About Insmed (NASDAQ: INSM)
›
Insmed (NASDAQ: INSM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,664 employees.
The shares were at 144.46 USD on 19 November 2026, down 22.2% over 52 weeks. Its 52-week range is 90.39 USD to 212.75 USD: the price is 32.1% below the high and 59.8% above the low.
Its market capitalisation is 31.69B USD.
Insmed reports return on equity of -172.8%, an operating margin of -41.7% and revenue up 268.4% year over year.
It holds more cash than debt, a net cash position of 415.69M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 22 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 194.18 USD is 34.4% above the current price. The next earnings report is expected on 18 February 2027.